WallStSmart

Edwards Lifesciences Corp (EW)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 233% more annual revenue ($20.98B vs $6.30B). EW leads profitability with a 17.4% profit margin vs 9.1%. GEHC appears more attractively valued with a PEG of 1.72. EW earns a higher WallStSmart Score of 61/100 (C+).

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 7.5Value: 6.0Quality: 4.8
Piotroski: 2/9

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+69.9%)

Margin of Safety

+69.9%

Fair Value

$263.84

Current Price

$83.98

$179.86 discount

UndervaluedFair: $263.84Overvalued
GEHCUndervalued (+43.5%)

Margin of Safety

+43.5%

Fair Value

$140.13

Current Price

$61.03

$79.10 discount

UndervaluedFair: $140.13Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW2 strengths · Avg: 9.0/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
14.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Areas to Watch

EW3 concerns · Avg: 3.0/10
PEG RatioValuation
2.074/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.4x2/10

Premium valuation, high expectations priced in

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.724/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.4x leaves little room for execution misses.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

EW profiles as a growth stock while GEHC is a value play — different risk/reward profiles.

GEHC carries more volatility with a beta of 1.30 — expect wider price swings.

EW is growing revenue faster at 16.7% — sustainability is the question.

EW generates stronger free cash flow (354M), providing more financial flexibility.

Bottom Line

EW scores higher overall (61/100 vs 57/100), backed by strong 17.4% margins and 16.7% revenue growth. GEHC offers better value entry with a 43.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?